Swelling

Alport Syndrome Market to Witness Upsurge in Growth at a Massive CAGR of 69% by 2034 | DelveInsight

Retrieved on: 
Wednesday, April 17, 2024
USD, Urine, ACE, Finerenone, ESRD, Kidney, Otorhinolaryngology, Nephrotoxicity, Mutation, Hearing, Diagnosis, Glomerular filtration rate, Hearing loss, Blood, Swelling, Proteinuria, Kidney failure, Cochlea, Alport syndrome, Nephrology, EU4, GFR, ADAS, Heredity, Research, Genetic counseling, Kidney disease, Novartis, ARAS, Ophthalmology, COL4A4, Patient, Kidney transplantation, LAS, Dialysis, DSM-IV codes, COL4A3, Quality of life, Genetic disorder, Gene, Pharmaceutical industry

LAS VEGAS, April 17, 2024 /PRNewswire/ -- DelveInsight's Alport Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, Alport syndrome emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Key Points: 
  • Leading Alport syndrome companies such as Eloxx Pharmaceuticals, Chinook Therapeutics (A Novartis company), Bayer, Calliditas Therapeutics, Evotec, and others are developing novel Alport syndrome drugs that can be available in the Alport syndrome market in the coming years.
  • The disorder manifests in different forms such as autosomal recessive Alport syndrome (ARAS), X-linked Alport syndrome (XLAS), and autosomal dominant Alport syndrome (ADAS).
  • The X-linked Alport syndrome (XLAS) is the most prevalent subtype of Alport syndrome with around 11K cases in 2023 in the US while autosomal dominant Alport syndrome (ADAS) is the least prevalent subtype of Alport syndrome.
  • To know more about Alport syndrome treatment guidelines, visit @ Alport Syndrome Management

InventHelp Inventor Develops New Earring to Help Heal Infected Piercing (SGJ-252)

Retrieved on: 
Wednesday, April 17, 2024
Suite, Sale, Multimedia, ICE, Red, Swelling, Petroleum jelly

PITTSBURGH, April 17, 2024 /PRNewswire/ -- "I wanted to create an earring that could apply antibacterial ointment to help heal infected piercings," said an inventor, from Cottonwood Heights, Utah, "so I invented the STERIL ICE.

Key Points: 
  • PITTSBURGH, April 17, 2024 /PRNewswire/ -- "I wanted to create an earring that could apply antibacterial ointment to help heal infected piercings," said an inventor, from Cottonwood Heights, Utah, "so I invented the STERIL ICE.
  • My design could help reduce and possibly eliminate pain, redness, swelling, and oozing blood or pus."
  • As a result, it helps heal infected or irritated piercings.
  • 22-SGJ-252, InventHelp, 100 Beecham Drive, Suite 110, Pittsburgh, PA 15205-9801, or call (412) 288-1300 ext.

Nexamp Raises $520M to Power Clean Energy Mission

Retrieved on: 
Wednesday, April 10, 2024
Diamond, Bank of America, Generate, Investment, Swelling, Partnership, Engineering, Acquisition, Inflation, BofA Securities, Community, Growth, IRA, CO, Renewable energy

BOSTON, April 10, 2024 /PRNewswire/ -- Nexamp, a leading independent renewable energy provider and the nation's largest community solar developer and owner, announced today that it has secured $520 million in a capital raise led by Manulife Investment Management, alongside existing investors Diamond Generating Corporation and Generate Capital. The company will leverage the investment to expedite deployment of its national project pipeline, accelerate expansion and developer partnerships in new and existing markets, and fuel the continued growth of its generation and consumer-driven offerings.     

Key Points: 
  • The scale of the investment reflects the immense surge in demand for renewable power across the country and a growing appreciation within the investor community of the essential need to balance utility-scale infrastructure with reliable distributed power solutions in navigating the clean energy transition.
  • "This landmark financing comes at a pivotal moment in the evolution of America's energy economy, and underscores the indispensable role of community solar in democratizing access to clean, affordable energy solutions for every American," said Nexamp CEO Zaid Ashai.
  • "This unprecedented investment reflects swelling confidence in the ability of independent renewable energy providers to reimagine outmoded infrastructure and reshape our grid.
  • "Nexamp has been at the forefront of a distributed energy revolution in the United States, and we're thrilled to expand our partnership."

Orphan designation: Diacerein Treatment of epidermolysis bullosa, 20/02/2014 Positive

Retrieved on: 
Thursday, April 18, 2024
Eurostat, Diagnosis, Civil service commission, Gene, Anthraquinones, Skin cancer, Epidermolysis bullosa, Disease, Inflammation, Patient, Committee, Knowledge, Regulation, Keratin, EMA, IRIS, Joint, Protein, Life expectancy, Deformity, Blister, Interleukin-1 family, Mouth, European, Skin, Collagen, COMP, Infection, Safety, European Commission, Pain, Osteoarthritis, Marketing, Swelling, FGK, Medicine, Pharmaceutical industry

Orphan designation: Diacerein Treatment of epidermolysis bullosa, 20/02/2014 Positive

Key Points: 


Orphan designation: Diacerein Treatment of epidermolysis bullosa, 20/02/2014 Positive

Bestqool Launches Innovative Red Light Therapy Devices for Eczema Relief

Retrieved on: 
Friday, April 5, 2024
Skin care, Fibroblast, Health, Certification, RLT, Psoriasis, Adenosine triphosphate, Cell, Serotonin, Patient, Photobiology, Tissue, Rosacea, Mitochondrion, Mental health, History, Red, Quality of life, Dermatitis, Itch, Keratinocyte, Acne, Skin, Pollution, Erythema, Cytokine, Irritation, ATP, Immune system, Recurrence, Fatigue, Swelling, FDA, Waste, Medical device

Bestqool's advanced red light therapy offers a non-invasive, natural solution for managing this pervasive skin issue.

Key Points: 
  • Bestqool's advanced red light therapy offers a non-invasive, natural solution for managing this pervasive skin issue.
  • Combining red light therapy with topical ointments can be a complementary approach for effective eczema treatment.
  • Bestqool's latest range of portable red light therapy devices are designed to be both convenient and effective for home use.
  • Adding red light therapy to daily care and prevention can repair both inside and outside by lowering eczema recurrence and improving the quality of life.

Don’t Drop the Ball! The Urology Care Foundation Urges Men to Check Themselves for Testicular Cancer Awareness Month

Retrieved on: 
Monday, April 1, 2024
Diagnosis, Health, American Urological Association, Breast, Risk, Testicular cancer, GCNIS, Medical college, Groin, Ache, Cancer, Epididymis, Scrotum, Male, Testicle, Thumb, Pain, AUA, Swelling, Courage, Birth control

BALTIMORE, April 01, 2024 (GLOBE NEWSWIRE) -- April is Testicular Cancer Awareness Month, and the Urology Care Foundation, the official foundation of the American Urological Association (AUA), is urging men not to drop the ball when it comes to their testicular health.

Key Points: 
  • BALTIMORE, April 01, 2024 (GLOBE NEWSWIRE) -- April is Testicular Cancer Awareness Month, and the Urology Care Foundation, the official foundation of the American Urological Association (AUA), is urging men not to drop the ball when it comes to their testicular health.
  • Testicular cancer is one of the less common cancers in men, with only 1 out of every 250 men getting diagnosed during their lifetime.
  • The best way to increase the chances we can cure someone of testicular cancer is to catch it early.
  • Prostate exams, scrotal exams, penis stuff, all of it,” said C. Freeman McCluskey, MD, testicular cancer survivor and urology resident at the Medical College of Georgia.

argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia

Retrieved on: 
Tuesday, March 26, 2024
Diagnosis, Blood pressure, Efgartigimod alfa, System, Urination, Urinary tract infection, MHLW, Chest pain, Rituximab, Allergy, Disease, Infection, Risk, Headache, Patient, Sore throat, IWG, History, ITP, Chills, Quality of life, Cough, Euronext, Rash, Respiratory tract infection, Splenectomy, Medicine, Skin, Fever, Antibody, Wheeze, Back pain, Shivering, Safety, Pain, Fatigue, Phlegm, Swelling, Food, Autoimmune disease, Nursing

“argenx is on a mission to deliver transformative medicines for people living with severe autoimmune disease,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx.

Key Points: 
  • “argenx is on a mission to deliver transformative medicines for people living with severe autoimmune disease,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx.
  • By reducing circulating autoantibodies, VYVGART is uniquely designed to serve as a precision intervention that targets the underlying disease biology of ITP.
  • ADVANCE successfully met its primary endpoint, demonstrating that a higher proportion of chronic ITP patients receiving VYVGART achieved a sustained platelet count response compared to placebo.
  • Do not use VYVGART if you have a serious allergy to efgartigimod alfa or any of the other ingredients in VYVGART.

KT® Introduces KT Ice: A Revolutionary Product Series for Enhanced Performance and Recovery

Retrieved on: 
Tuesday, April 9, 2024
Arthralgia, KT, Menthol, Vasoconstriction, Exercise, Relaxation, Thermoreceptor, ICE, Arnica, Sensation, Muscle soreness, Swelling, Video game

AMERICAN FORK, Utah, April 9, 2024 /PRNewswire/ -- KT®, the leading kinesiology tape brand, is proud to announce the launch of KT Ice, a groundbreaking series of products designed to revolutionize the way consumers prepare, perform, and recover from physical activity. The KT Ice series features a comprehensive range of products tailored to support individuals at every stage of their fitness journey.

Key Points: 
  • Additionally, menthol facilitates vasoconstriction, inhibits pain and inflammation channels, and enhances overall recovery, making it an invaluable component of the KT Ice series.
  • "The KT Ice series represents a paradigm shift in how individuals approach preparation, performance, and recovery," said Jessica Klodnicki, KT CEO.
  • "With the launch of the KT Ice series, KT® is proud to make clinically inspired recovery solutions available to the everyday active consumer.
  • The KT Ice series also introduces two new magnesium creams: KT HEALTH ACTIVATE and KT HEALTH RECOVER.

Orphan designation: Nirogacestat Treatment of soft tissue sarcoma, 17/10/2019 Positive

Retrieved on: 
Tuesday, April 9, 2024
Eurostat, Diagnosis, Civil service commission, Plantar fibromatosis, Radiation, Gene, Growth, Sarcoma, Blood, Disease, Patient, Committee, Knowledge, Tissue, Regulation, Cancer, EMA, IRIS, Radiation therapy, European, Therapy, COMP, Aggressive fibromatosis, Safety, European Commission, GS, Pain, Marketing, Swelling, Medicine, Pharmaceutical industry

Orphan designation: Nirogacestat Treatment of soft tissue sarcoma, 17/10/2019 Positive

Key Points: 


Orphan designation: Nirogacestat Treatment of soft tissue sarcoma, 17/10/2019 Positive

Orphan designation: Florilglutamic acid (18F) Diagnosis of hepatocellular carcinoma, 21/03/2016 Withdrawn

Retrieved on: 
Tuesday, April 9, 2024
Eurostat, Diagnosis, Civil service commission, Radiation, MRI, Weakness, Cell, Hepatitis B, Disease, Infection, Magnetic resonance imaging, Cirrhosis, Patient, Committee, Weight loss, Knowledge, PET, Neoplasm, Abdomen, Tissue, Regulation, Cancer, EMA, IRIS, Hepatocellular carcinoma, Woman, Nausea, European, COMP, Sponsor, European Commission, Safety, Pain, Molecular imaging, Marketing, Swelling, Liver, Medicine, Pharmaceutical industry

Orphan designation: Florilglutamic acid (18F) Diagnosis of hepatocellular carcinoma, 21/03/2016 Withdrawn

Key Points: 


Orphan designation: Florilglutamic acid (18F) Diagnosis of hepatocellular carcinoma, 21/03/2016 Withdrawn